Diabetic neuropathy: pathogenesis and therapy (Q33731683)

29 July 2017

1 reference

title

Diabetic neuropathy: pathogenesis and therapy (English)

1 reference

29 July 2017

1 reference

Vinik AI

1

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 August 1999

1 reference

American Journal of Medicine

29 July 2017

published in

1 reference

29 July 2017

volume

107

1 reference

29 July 2017

issue

2B

1 reference

29 July 2017

page(s)

17S-26S

1 reference

Consensus statement: Report and recommendations of the San Antonio conference on diabetic neuropathy. American Diabetes Association American Academy of Neurology

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Nerve biopsy findings in different patterns of proximal diabetic neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Successful treatment of neuropathies in patients with diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Phospholipid and glutamic acid decarboxylase autoantibodies in diabetic neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Transperineurial Capillary Abnormalities in the Sural Nerve of Patients with Diabetic Neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Capillary number and percentage closed in human diabetic sural nerve

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Abnormalities of endoneurial microvessels and sural nerve pathology in diabetic neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Nerve growth factor protects adult sensory neurons from cell death and atrophy caused by nerve injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Effect of glycemic control on serum insulin-like growth factors in diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Measurement of insulin-like growth factor-II in physiological fluids and tissues. I. An improved extraction procedure and radioimmunoassay for human and rat fluids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Structure and biological activity of basement membrane proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Nerve growth factor, laminin, and fibronectin promote neurite growth in human fetal sensory ganglia cultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Laminin is associated with the "neurite outgrowth-promoting factors" found in conditioned media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Neurite-promoting factors and extracellular matrix components accumulating in vivo within nerve regeneration chambers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Laminin promotes neuritic regeneration from cultured peripheral and central neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Rapid effects of laminin on the growth cone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Differential laminin gene expression in dorsal root ganglion neurons and nonneuronal cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Up-Regulation of Laminin B2 Gene Expression in Dorsal Root Ganglion Neurons and Nonneuronal Cells during Sciatic Nerve Regeneration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

7 January 2021

Diabetic neuropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Entrapment neuropathies of the upper extremities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Management of diabetic neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

The apoptotic death of neuroblastoma cells caused by serum from patients with insulin-dependent diabetes and neuropathy may be Fas-mediated

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy - a clinical and neurophysiological study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Clinical trial of an aldose reductase inhibitor in diabetic neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Effect of an aldose reductase inhibitor on diabetic peripheral neuropathy. Preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Aldose reductase inhibition improves nerve conduction velocity in diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

A Controlled Trial of Sorbinil, an Aldose Reductase Inhibitor, in Chronic Painful Diabetic Neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

The effect of an aldose reductase inhibitor (Sorbinil) on diabetic neuropathy and neural function of the retina: a double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

A Double Blind Placebo Controlled Trial of Mixed Gangliosides in Diabetic Peripheral and Autonomic Neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Treatment of Painful Diabetic Polyneuropathy with Mixed Gangliosides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Ganglioside treatment in diabetic peripheral neuropathy: A multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Ganglioside therapy in diabetic neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Treatment of diabetic neuropathy with gamma-linolenic acid. The gamma-Linolenic Acid Multicenter Trial Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Slowing of peripheral motor nerve conduction was ameliorated by aminoguanidine in streptozocin-induced diabetic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Effect of aminoguanidine on the frequency of neuroaxonal dystrophy in the superior mesenteric sympathetic autonomic ganglia of rats with streptozocin-induced diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Oral supplementation of myoinositol: effects on peripheral nerve function in human diabetics and on the concentration in plasma, erythrocytes, urine and muscle tissue in human diabetics and normals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Neurotrophic factors in the therapy of diabetic neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Apolipoprotein(a) and cardiovascular disease in Type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Diurnal blood pressure variations in normoalbuminuric type 1 diabetic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Circadian variation of blood pressure in autonomic failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Progressive treatment of erectile dysfunction with intracorporeal injections of different combinations of vasoactive agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Peripheral Diabetic Neuropathy Treated With Amitriptyline and Fluphenazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy. A double-blind cross-over study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

A systematic review of antidepressants in neuropathic pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Phenytoin in the treatment of diabetic symmetrical polyneuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol�): Double blind crossover trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Anticonvulsant drugs for management of pain: a systematic review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

The effect of gabapentin on neuropathic pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Capsaicin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Symptomatic treatment of painful neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Mexiletine in the treatment of diabetic neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. The Mexiletine Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900009-1

10.1016/S0002-9343(99)00009-1

7 January 2021

Identifiers

DOI

1 reference

29 July 2017

1 reference